Gene therapy patients monitored for years to ensure lasting safety

NCT ID NCT05145062

First seen Nov 12, 2025 · Last updated May 16, 2026 · Updated 27 times

Summary

This study follows 8 people with severe sickle cell disease or transfusion-dependent beta-thalassemia who already received a gene therapy called BIVV003 or ST-400. Researchers will check for side effects, survival, and how well the treatment controls their disease over many years. The goal is to make sure the therapy remains safe and effective long-term.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLOOD AND LYMPHATIC DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Boston Children's Hospital

    Boston, Massachusetts, 02115, United States

  • Children's Healthcare of Atlanta

    Atlanta, Georgia, 30329, United States

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • UCSF Benioff Children's Hospital

    Oakland, California, 94609, United States

  • University of California Davis Health System

    Sacramento, California, 95817, United States

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

Conditions

Explore the condition pages connected to this study.